Cystic fibrosis in adults

Česká verzia

Authors: Libor Fila
Authors place of work: Pneumologická klinika 2. LF UK a FN Motol, Praha
Published in the journal: Vnitř Lék 2017; 63(11): 834-842
Category: Reviews

Summary

Cystic fibrosis (CF) is an inherited disease caused by mutations in the transmembrane conductance regulator (CFTR) gene. The disease leads to dysfunction of the exocrine glands with high concentration of chloride in the sweat and formation of abnormally viscous mucus in the respiratory, digestive and reproductive tract. Chronic sinopulmonary disease, exocrine pancreatic insufficiency, liver disease, intestinal obstruction, impaired nutritional status, salt loss syndrome and male infertility dominates in the clinical presentation. The examination of sweat chloride concentration and mutations in the CFTR gene is used in CF diagnostics for detection of CFTR protein dysfunction. The treatment comprises especially respiratory physiotherapy with mucolytics inhalations, aggressive antibiotic therapy and high-calorie diet together with adequate pancreatic enzymes substitution. The prevention of airway infection with resistant bacterial pathogens, particularly Pseudomonas aeruginosa, is a fundamental measure. Significant recent progress include the use of newborn screening of CF and drugs targeted to individual CFTR gene mutations in the clinical practise. The prognosis of patients has improved due to using of modern therapeutic methods in CF treatment centres. Children born at present time have survival probability 40–50 years.

Key words:
adults – cystic fibrosis – diagnostics – therapy

Zdroje

2. Fila L, Sedlák V, Binková I et al. Dvacet let péče o dospělé nemocné s cystickou fibrózou v České republice. Vnitř Lék 2009; 55(6): 542–548.

3. Boyle MP, De Boeck K. A new era in the treatment of cystic fibrosis: correction of the underlying CFTR defect. Lancet Respir Med 2013; 1(2): 158–163. Dostupné z DOI: <http://dx.doi.org/10.1016/S2213–2600(12)70057–7>.

4. Křenková P, Piskáčková T, Holubová et al. Distribution of CFTR mutations in the Czech population: Positive impact of integrated clinical and laboratory expertise, detection of novel/de novo alleles and relevance for related/derived populations. J Cyst Fibros 2013; 12(5): 532–537. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jcf.2012.12.002>.

5. Boucher RC. New concepts of the pathogenesis of cystic fibrosis lung disease. Eur Respir J 2004; 23(1): 146–158.

6. Fila L. Cystická fibróza. In: Kolek V, Kašák V, Vašáková M et al. Pneumologie. 2. ed. Maxdorf: Praha 2014: 416–420. Dostupné z DOI: <http://dx.doi.org/978–80–7345–387–9>.

7. Yankaskas JR, Marshall BC, Sufian B et al. Cystic fibrosis adult care: consensus conference report. Chest 2004; 125(1 Suppl): S1-S39.

8. Stevens DA, Moss RB, Kurup VP et al. Participants in the Cystic Fibrosis Foundation Consensus Conference. Allergic bronchopulmonary aspergillosis in cystic fibrosis – state of the art: Cystic Fibrosis Foundation Consensus Conference. Clin Infect Dis 2003; 37(Suppl 3): S225-S264.

9. Floto RA, Olivier KN, Saiman L et al. US Cystic Fibrosis Foundation and European Cystic Fibrosis Society. US Cystic Fibrosis Foundation and European Cystic Fibrosis Society consensus recommendations for the management of non-tuberculous mycobacteria in individuals with cystic fibrosis. Thorax 2016; 71(Suppl 1): i1-i22. Dostupné z DOI: <http://dx.doi.org/10.1136/thoraxjnl-2015–207360>.

10. Walkowiak J, Lisowska A, Blaszczyński M. The changing face of the exocrine pancreas in cystic fibrosis: pancreatic sufficiency, pancreatitis and genotype. Eur J Gastroenterol Hepatol 2008; 20(3): 157–160. Dostupné z DOI: <http://dx.doi.org/10.1097/MEG.0b013e3282f36d16>.

11. Kelly A, Moran A. Update on cystic fibrosis-related diabetes. J Cyst Fibros 2013; 12(4): 318–331. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jcf.2013.02.008>.

12. Aris RM, Merkel PA, Bachrach LK et al. Guide to bone health and disease in cystic fibrosis. J Clin Endocrinol Metab 2005; 90(3): 1888–1896.

13. Mousa HM, Woodley FW. Gastroesophageal reflux in cystic fibrosis: current understandings of mechanisms and management. Curr Gastroenterol Rep 2012; 14(3): 226–235. Dostupné z DOI: <http://dx.doi.org/10.1007/s11894–012–0261–9>.

14. Colombo C, Ellemunter H, Houwen R et al. ECFS. Guidelines for the diagnosis and management of distal intestinal obstruction syndrome in cystic fibrosis patients. J Cyst Fibros 2011; 10(Suppl 2): S24-S28. Dostupné z DOI: <http://dx.doi.org/10.1016/S1569–1993(11)60005–2>.

15. Debray D, Kelly D, Houwen R et al. Best practice guidance for the diagnosis and management of cystic fibrosis-associated liver disease. J Cyst Fibros 2011; 10(Suppl 2): S29-S36. Dostupné z DOI: <http://dx.doi.org/10.1016/S1569–1993(11)60006–4>.

16. Davé S, Honney S, Raymond J et al. An unusual presentation of cystic fibrosis in an adult. Am J Kidney Dis 2005; 45(3): e41-e44. Dostupné z DOI: <http://dx.doi.org/10.1053/j.ajkd.2004.11.009>.

17. Wong PY. CFTR gene and male fertility. Mol Hum Reprod 1998; 4(2): 107–110.

18. Edenborough FP, Borgo G, Knoop C et al. European Cystic Fibrosis Society. Guidelines for the management of pregnancy in women with cystic fibrosis. J Cyst Fibros 2008; 7(Suppl 1): S2-S32.

19. Farrell PM, White TB, Ren CL et al. Diagnosis of Cystic Fibrosis: Consensus Guidelines from the Cystic Fibrosis Foundation. J Pediatr 2017; 181(Suppl): S4-S15.e1. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jpeds.2016.09.064>.

20. Farrell PM, White TB, Derichs N et al. Cystic Fibrosis Diagnostic Challenges over 4 Decades: Historical Perspectives and Lessons Learned. J Pediatr 2017; 181(Suppl): S16-S26. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jpeds.2016.09.067>.

21. De Boeck K, Derichs N, Fajac I et al. [ECFS Diagnostic Network Working Group. EuroCareCF WP3 Group on CF diagnosis]. New clinical diagnostic procedures for cystic fibrosis in Europe. J Cyst Fibros 2011; 10(Suppl 2): S53-S66. Dostupné z DOI: <http://dx.doi.org/10.1016/S1569–1993(11)60009-X>.

22. Fila L, Grandcourtová A, Valentová Bartáková L et al. Diagnostika cystické fibrózy u dospělých. Vnitř Lék 2016; 62(5): 360–364.

23. Mogayzel PJ Jr, Naureckas ET, Robinson KA et al. Pulmonary Clinical Practice Guidelines Committee. Cystic fibrosis pulmonary guidelines. Chronic medications for maintenance of lung health. Am J Respir Crit Care Med 2013; 187(7): 680–689.

24. Bhatt JM. Treatment of pulmonary exacerbations in cystic fibrosis. Eur Respir Rev 2013; 22(129): 205–216. Dostupné z DOI: <http://dx.doi.org/10.1183/09059180.00006512>.

25. Flume PA, Mogayzel PJ Jr, Robinson KA et al. [Clinical Practice Guidelines for Pulmonary Therapies Committee. Cystic Fibrosis Foundation Pulmonary Therapies Committee]. Cystic fibrosis pulmonary guidelines: pulmonary complications: hemoptysis and pneumothorax. Am J Respir Crit Care Med 2010; 182(3): 298–306. Dostupné z DOI: <http://dx.doi.org/10.1164/rccm.201002–0157CI>.

26. Turck D, Braegger CP, Colombo C et al. ESPEN-ESPGHAN-ECFS guidelines on nutrition care for infants, children, and adults with cystic fibrosis. Clin Nutr 2016; 35(3): 557–577. Dostupné z DOI: <http://dx.doi.org/10.1016/j.clnu.2016.03.004>.

27. Saiman L, Siegel JD, LiPuma JJ et al. Infection prevention and control guideline for cystic fibrosis: 2013 update. Infect Control Hosp Epidemiol 2014; 35(Suppl 1): S1-S67. Dostupné z DOI: <http://dx.doi.org/10.1086/676882>.

28. Tuchman LK, Schwartz LA, Sawicki GS et al. Cystic fibrosis and transition to adult medical care. Pediatrics 2010; 125(3): 566–573. Dostupné z DOI: <http://dx.doi.org/10.1542/peds.2009–2791>.

29. Ramsey BW, Davies J, McElvaney NG et al. VX08–770–102 Study Group. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. N Engl J Med 2011; 365(18): 1663–1672. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa1105185>.

30. Conway S, Balfour-Lynn IM, De Rijcke K et al. European Cystic Fibrosis Society Standards of Care: Framework for the Cystic Fibrosis Centre. Cyst Fibros 2014; 13(Suppl 1): S3-S22. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jcf.2014.03.009>.